Avelumab in metastatic castration-resistant prostate cancer (mCRPC).

Fakhrejahani, F; Madan, RA; Dahut, WL; Bilusic, M; Karzai, F; Cordes, LM; Strauss, J; Schlom, J; Gulley, JL

JOURNAL OF CLINICAL ONCOLOGY, 2017; 35 ( ):